Search results

Search:
in the keywords: cancer diagnostics

Sort By:

Limit search:

MRI as a potential tool for monitoring of therapeutic monoclonal antibody distribution in cancer patients

100%

Tabarkiewicz J., Aebisher D., Bartusik-Aebisher D.

Acta Poloniae Pharmaceutica - Drug Research

2020

vol. 77

issue 3

383-389

Imaging and quantification of MAbs distribution by MRI after administration in vivo can improve patient outcomes, although it is not routinely used in the clinic hence the motivation for development of new MAbs imaging methodologies. Improvements in imaging and quantification of antibody distributions can be made by conjugating MAbs to “hotspot” atoms such as 19F as 19F Currently, research investigating the incorporation of 19F to antibody delivery systems has been limited to trastuzumab perfluorocarbon emulsions and this method has not been extended to other clinically approved antibodies. The methodologies of 19F MRI can improve current limitations of antibody immunotherapy such as quantitative visualization of targeted surface antigens expressed on tumor cells.

Metaloproteinazy – znaczenie w procesie nowotworzenia, diagnostyce i terapii

63%

Pietrzak J., Mirowski M.

Folia Medica Lodziensia

2015

vol. 42

issue 1

33-48

Metalloproteinases (MMP) are proteolytic enzymes whose activity is determined by the presence of zinc ion in the active site and are a widely distributed family of protease to ensure the preservation of homeostasis in animals. In human body they also play many important functions participating in the process of embryogenesis as well as in the formation of blood cells or bone formation. The main role, as it seemed at the beginning research on this group of enzymes, was to digest the extracellular matrix. However, over the years, it turned out that metalloproteinases are important part in the regulation of cell biology, in particular a tumor cell. Studies have confirmed the participation of metalloproteinases in all stages of the process of carcinogenesis. At the moment, there are numerous reports of available of various MMPs in different tumors. However, two of these MMP–2 and MMP–9 belonging to the gelatinases seem to be the most common. It has been confirmed also that higher levels usually indicate a worse prognosis for the patient. Therefore, they may prove to be a valuable prognostic indication for clinicians. Attention was paid to the potential use of matrix metalloproteinases in targeted therapy. The pharmaceutical industry has long been trying to launch metalloproteinase inhibitors as possible therapeutics in cancer, seeing in them a potential that, however, is limited to the early stages of development. After initial setbacks related primarily to the low selectivity is used at once more modern methods as monoclonal antibodies or liposomal drug delivery system. Thus, giving the possibility of treatment that does not cause so enormous side effects as conventional therapy.

Refine search results

1 Acta Poloniae Pharmaceutica - Drug Research

1 Folia Medica Lodziensia

1 2020

1 2015

1 Aebisher D.

1 Bartusik-Aebisher D.

1 Mirowski M.

1 Pietrzak J.

1 Tabarkiewicz J.

Search results

MRI as a potential tool for monitoring of therapeutic monoclonal antibody distribution in cancer patients

Metaloproteinazy – znaczenie w procesie nowotworzenia, diagnostyce i terapii